Tirzepatide, a dual GIP and GLP-1 receptor agonist, demonstrates pleiotropic benefits on glycemic control, body weight regulation, lipid metabolism, and cardiorenal outcomes.
This narrative review outlines the mechanisms of action and broad clinical effects of tirzepatide across metabolic and cardiorenal conditions.
Tirzepatide is the first dual long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist indicated for the treatment of type 2 diabetes in adults, for reducing excess body weight and maintaining long-term weight reduction in adults with obesity or overweight and at least one weight-related comorbid condition, and for treating obstructive sleep apnea in adults with obesity. Recent studies found beneficial effects on heart failure with preserved ejection fraction and on metabolic dysfunction-associated steatohepatitis; its effects on cardiovascular outcomes in people with type 2 diabetes, as well as on reducing morbidity and mortality in people with obesity/overweight, remain under investigation. Here, we review the mechanistic activity of tirzepatide and its effect on glycemic control, body weight, the cardiorenal system, and lipid metabolism.
Galindo et al. (Thu,) conducted a review in Type 2 diabetes and obesity. Tirzepatide was evaluated. Tirzepatide, a dual GIP and GLP-1 receptor agonist, demonstrates pleiotropic benefits on glycemic control, body weight regulation, lipid metabolism, and cardiorenal outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: